IGM Biosciences - IGMS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $40.36
  • Forecasted Upside: 92.94 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$20.92
▼ -0.08 (-0.38%)

This chart shows the closing price for IGMS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IGM Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IGMS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IGMS

Analyst Price Target is $40.36
▲ +92.94% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for IGM Biosciences in the last 3 months. The average price target is $40.36, with a high forecast of $65.00 and a low forecast of $22.00. The average price target represents a 92.94% upside from the last price of $20.92.

This chart shows the closing price for IGMS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in IGM Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2022Jefferies Financial GroupReiterated RatingBuy$61.00 ➝ $55.00Low
11/7/2022HC WainwrightLower TargetBuy$58.00 ➝ $45.00Low
11/4/2022Royal Bank of CanadaLower TargetSector Perform$27.00 ➝ $22.00Low
10/17/2022JPMorgan Chase & Co.Initiated CoverageNeutral$27.00Low
8/29/2022Bank of AmericaInitiated CoverageBuy$34.00Low
8/23/2022Truist FinancialLower TargetBuy$74.00 ➝ $37.00Low
8/15/2022GuggenheimLower Target$40.00N/A
6/1/2022Robert W. BairdLower TargetOutperform$46.00 ➝ $31.00Medium
5/17/2022HC WainwrightLower TargetBuy$59.00 ➝ $58.00N/A
4/4/2022Robert W. BairdLower TargetOutperform ➝ Outperform$65.00 ➝ $46.00Low
3/31/2022WedbushLower Target$67.00 ➝ $58.00Low
3/31/2022HC WainwrightLower TargetBuy$76.00 ➝ $59.00Low
3/30/2022Truist FinancialLower TargetBuy$80.00 ➝ $74.00High
3/30/2022Morgan StanleyBoost TargetEqual Weight$25.00 ➝ $30.00High
1/3/2022GuggenheimLower Target$100.00 ➝ $55.00High
12/16/2021HC WainwrightReiterated RatingBuy$114.00 ➝ $76.00Low
12/14/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$100.00 ➝ $38.00Low
12/14/2021Robert W. BairdLower TargetOutperform ➝ Outperform$90.00 ➝ $65.00High
12/13/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$100.00 ➝ $38.00Medium
12/13/2021Jefferies Financial GroupBoost TargetBuy$101.00 ➝ $126.00High
12/13/2021Stifel NicolausLower TargetBuy ➝ Buy$98.00 ➝ $65.00High
12/13/2021WedbushLower TargetOutperform ➝ Outperform$82.00 ➝ $67.00High
12/13/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$90.00 ➝ $51.00High
11/5/2021Royal Bank of CanadaLower TargetOutperform$110.00 ➝ $90.00High
11/5/2021WedbushUpgradeNeutral ➝ Outperform$82.00High
8/26/2021Morgan StanleyInitiated CoverageOverweight$100.00Low
8/16/2021WedbushBoost TargetNeutral$77.00 ➝ $82.00High
8/10/2021HC WainwrightReiterated RatingBuy$114.00Medium
3/31/2021Truist FinancialBoost Target$86.00 ➝ $119.00Medium
3/31/2021HC WainwrightReiterated RatingBuyMedium
1/29/2021Royal Bank of CanadaInitiated CoverageOutperform$121.00Low
1/19/2021HC WainwrightBoost TargetBuy$88.00 ➝ $114.00High
12/22/2020WedbushDowngradeOutperform ➝ Neutral$73.00 ➝ $77.00Medium
12/6/2020Piper SandlerBoost TargetOverweight$81.00 ➝ $89.00High
7/16/2020Robert W. BairdInitiated CoverageOutperform$90.00Low
7/1/2020HC WainwrightInitiated CoverageBuy$88.00Medium
6/30/2020Stifel NicolausBoost TargetBuy$67.00 ➝ $95.00High
5/28/2020SunTrust BanksInitiated CoverageBuy$86.00High
5/8/2020Stifel NicolausBoost TargetBuy$60.00 ➝ $67.00Medium
5/8/2020Piper SandlerBoost TargetOverweight$53.00 ➝ $81.00Medium
4/21/2020WedbushInitiated CoverageOutperformMedium
3/12/2020Wolfe ResearchInitiated CoverageOutperformHigh
2/3/2020Stifel NicolausBoost TargetBuy$52.00 ➝ $32.00Medium
1/6/2020Piper Jaffray CompaniesBoost TargetOverweight$26.00 ➝ $53.00N/A
10/14/2019Jefferies Financial GroupInitiated CoverageBuy$25.00High
10/14/2019Stifel NicolausInitiated CoverageBuy$32.00High
10/14/2019GuggenheimInitiated CoverageBuy$30.00High
10/13/2019Piper Jaffray CompaniesInitiated CoverageOverweight$26.00High
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
9/5/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/4/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/4/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
IGM Biosciences logo
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $20.92
Low: $19.66
High: $21.53

50 Day Range

MA: $20.66
Low: $16.05
High: $26.02

52 Week Range

Now: $20.92
Low: $12.67
High: $53.92

Volume

295,800 shs

Average Volume

506,960 shs

Market Capitalization

$895.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IGM Biosciences?

The following Wall Street research analysts have issued research reports on IGM Biosciences in the last twelve months: Bank of America Co., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, Truist Financial Co., and Wedbush.
View the latest analyst ratings for IGMS.

What is the current price target for IGM Biosciences?

11 Wall Street analysts have set twelve-month price targets for IGM Biosciences in the last year. Their average twelve-month price target is $40.36, suggesting a possible upside of 92.9%. Stifel Nicolaus has the highest price target set, predicting IGMS will reach $65.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $22.00 for IGM Biosciences in the next year.
View the latest price targets for IGMS.

What is the current consensus analyst rating for IGM Biosciences?

IGM Biosciences currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IGMS will outperform the market and that investors should add to their positions of IGM Biosciences.
View the latest ratings for IGMS.

What other companies compete with IGM Biosciences?

How do I contact IGM Biosciences' investor relations team?

IGM Biosciences' physical mailing address is 325 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company's listed phone number is 650-965-7873. The official website for IGM Biosciences is igmbio.com. Learn More about contacing IGM Biosciences investor relations.